Peter Altman
Chief Executive Officer at BIOCARDIA INC
Net worth: 227 390 $ as of 2024-03-30
Profile
Peter Alan Altman is the founder of CareDx, Inc. (founded in 1998) and Lumen Therapeutics (founded in 2004).
He was the Director at CareDx, Inc. from 2003 to 2014 and the Chief Executive Officer at Lumen Therapeutics from 2004 to 2005.
Dr. Altman's current jobs include being the President, Chief Executive Officer & Director at BioCardia, Inc. since 2002, the Chief Executive Officer at BioCardia Lifesciences, Inc., and a Director at Oncocyclist Biotech since 2018.
Dr. Altman's former jobs include being the President, Chief Executive Officer & Director at BioCardia, Inc. and a Principal at Ventritex, Inc. Dr. Altman received a doctorate degree from the University of California, Berkeley and The University of California, San Francisco.
He also received undergraduate and graduate degrees from the Fu Foundation School of Engineering & Applied Science.
Dr. Altman is also the founder of Sinus Rhythm Technologies, Inc...
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOCARDIA, INC.
2.16% | 2024-04-18 | 558,697 ( 2.16% ) | 227 390 $ | 2024-03-30 |
Peter Altman active positions
| Companies | Position | Start |
|---|---|---|
| BIOCARDIA INC | Chief Executive Officer | 2001-12-31 |
| Oncocyclist Biotech | Director/Board Member | 2017-12-31 |
BioCardia Lifesciences, Inc.
 BioCardia Lifesciences, Inc. BiotechnologyHealth Technology BioCardia Lifesciences, Inc. engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in Los Angeles, CA. | Chief Executive Officer | - |
Former positions of Peter Altman
| Companies | Position | End |
|---|---|---|
| CAREDX, INC | Founder | 2013-12-31 |
Lumen Therapeutics
 Lumen Therapeutics Pharmaceuticals: MajorHealth Technology Lumen Therapeutics is an American biopharmaceutical company. The private company was founded by Peter Alan Altman. | Chief Executive Officer | 2004-12-31 |
BioCardia, Inc. /Old/
 BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Chief Executive Officer | - |
Ventritex, Inc.
 Ventritex, Inc. Medical SpecialtiesHealth Technology Ventritex, Inc. designs, develops, manufactures and markets implantable defibrillators and related products for the treatment of ventricular tachycardia and ventricular fibrillation. | Corporate Officer/Principal | - |
Sinus Rhythm Technologies, Inc.
 Sinus Rhythm Technologies, Inc. Medical SpecialtiesHealth Technology Sinus Rhythm Technologies, Inc. develops devices for the prevention of atrial fibrillation. It treats causes of atrial fibrillation with an implanted apparatus that creates scar tissue and blocks electrical current. The company was founded by Robert A. van Tassel and Daniel J. Sullivan is headquartered in Plymouth, MN. | Corporate Officer/Principal | - |
Training of Peter Altman
| University of California, Berkeley | Doctorate Degree |
| The University of California, San Francisco | Doctorate Degree |
| Fu Foundation School of Engineering & Applied Science | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CAREDX, INC | Health Technology |
| BIOCARDIA INC | Health Technology |
| Private companies | 6 |
|---|---|
Ventritex, Inc.
Ventritex, Inc. Medical SpecialtiesHealth Technology Ventritex, Inc. designs, develops, manufactures and markets implantable defibrillators and related products for the treatment of ventricular tachycardia and ventricular fibrillation. | Health Technology |
Sinus Rhythm Technologies, Inc.
Sinus Rhythm Technologies, Inc. Medical SpecialtiesHealth Technology Sinus Rhythm Technologies, Inc. develops devices for the prevention of atrial fibrillation. It treats causes of atrial fibrillation with an implanted apparatus that creates scar tissue and blocks electrical current. The company was founded by Robert A. van Tassel and Daniel J. Sullivan is headquartered in Plymouth, MN. | Health Technology |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Health Technology |
Lumen Therapeutics
Lumen Therapeutics Pharmaceuticals: MajorHealth Technology Lumen Therapeutics is an American biopharmaceutical company. The private company was founded by Peter Alan Altman. | Health Technology |
BioCardia Lifesciences, Inc.
BioCardia Lifesciences, Inc. BiotechnologyHealth Technology BioCardia Lifesciences, Inc. engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in Los Angeles, CA. | Health Technology |
| Oncocyclist Biotech |
- Stock Market
- Insiders
- Peter Altman
